SynBiotic SE (FRA:SBX)
Germany · Delayed Price · Currency is EUR | Market Cap | 24.48M |
| Revenue (ttm) | 3.86M |
| Net Income (ttm) | -10.63M |
| Shares Out | n/a |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,956 |
| Average Volume | 6,506 |
| Open | 3.205 |
| Previous Close | 3.110 |
| Day's Range | 3.160 - 3.475 |
| 52-Week Range | 2.550 - 7.580 |
| Beta | n/a |
| RSI | 58.98 |
| Earnings Date | Aug 15, 2025 |
About Paramount Global
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany. [Read more]
Financial Performance
In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.
Financial StatementsNews
SynBiotic Eyes Triple Revenue by 2027 in Cannabis & Hemp Markets
SYNBIOTIC SE is set to triple its revenue by 2027, leveraging growth in medical cannabis and industrial hemp markets, with a strategic focus on sustainable expansion and unique investment opportunitie...
EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 23.04.2025 / 09:22 CET/CEST The issuer is solely responsi...